A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Abstract
Context. —EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders. Its use in dementias is based on positive results from only a few controlled clinical trials, most of which did not include standard assessments of cognition and behavior. Objective. —To assess the efficacy and safety of EGb in Alzheimer disease and multi-infarct dementia. Design. —A 52-week, randomized double-blind, placebo-controlled, parallelgroup, multicenter study. Patients. —Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia, without other significant medical conditions. Intervention. —Patients assigned randomly to treatment with EGb (120 mg/d) or placebo. Safety, compliance, and drug dispensation were monitored every 3 months with complete outcome evaluation at 12, 26, and 52 weeks. Primary Outcome Measures. —Alzheimer's Disease Assessment Scale—Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC). Results. —From 309 patients included in an intent-to-treat analysis, 202 provided evaluable data for the 52-week end point analysis. In the intent-to-treat analysis, the EGb group had an ADAS-Cog score 1.4 points betterthan the placebo group (P=.04) and a GERRI score 0.14 points better than the placebo group (P=.004). The same patterns were observed with the evaluable data set in which 27% of patients treated with EGb achieved at least a 4-point improvement on the ADAS-Cog, compared with 14% taking placebo (P=.005); on the GERRI, 37% were considered improved with EGb, compared with 23% taking placebo (P=.003). No difference was seen in the CGIC. Regarding the safety profile of EGb, no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events. Conclusions. —EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Modest cognitive function enhancement was noted in Alzheimer's disease subjects in numerous randomized, placebo-controlled, double-blind clinical trials.
“Modest cognitive function enhancement was noted in AD subjects in numerous randomized, placebo-controlled, double-blind clinical trials [126,127].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [126]
A 70-year-old man developed spontaneous hyphema after taking a 40 mg tab of concentrated Ginkgo.
“a case of a 70-year-old man who developed spontaneous hyphema after taking a 40 mg tab of concentrated Ginkgo was later reported [106]”
From Phytotherapy: A promising approach for the treatment of Alzheimer's disease (2022) · cites this paper as [106]
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
The Global Deterioration Scale for assessment of primary degenerative dementia
Reisberg, ., Ferris, S. H., de Leon, M. J., & Crook, T. H. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,982 · see citing works
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175 · see citing works
Population-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA · doi:10.1001/jama.1993.03500180078038 · Cited by 2,906 · see citing works
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · see citing works
The prevalence of dementia: A quantitative integration of the literature
Jorm, A. F., Korten, A. E., & Henderson, A. S. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02906.x · Cited by 1,301 · see citing works
Chui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201 · see citing works
Anthony, J. C., LeResche, L., Niaz, U., Korff, M. R. V., & Folstein, M. F. (1982) · Psychological Medicine · doi:10.1017/s0033291700046730 · Cited by 1,105 · see citing works
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 997 · see citing works
Welsh-Bohmer, K. A., Butters, N., Hughes, J. P., Mohs, R. C., & Heyman, A. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530150046016 · Cited by 721 · see citing works
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. R. (1992) · JAMA · doi:10.1001/jama.268.18.2523 · Cited by 632 · see citing works
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626 · see citing works
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408 · see citing works
Kanowski, S., Herrmann, W., Stephan, K., Wierich, W., & Hörr, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979544 · Cited by 369 · see citing works
Are reactive oxygen species involved in Alzheimer's disease?
Benzi, G. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00066-n · Cited by 365 · see citing works
Validation of clinical diagnostic criteria for Alzheimer's disease
Morris, J. C., McKeel, D. W., Fulling, K., Torack, R. M., & Berg, L. (1988) · Annals of Neurology · doi:10.1002/ana.410240105 · Cited by 362 · see citing works
Ginkgo biloba for cerebral insufficiency.
Kleijnen, J., & Knipschild, P. G. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb05642.x · Cited by 339 · see citing works
The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials
Gillings, D. B., & Koch, G. G. (1991) · Drug Information Journal · doi:10.1177/009286159102500311 · Cited by 230 · see citing works
The Clinician Interview‐ Based Impression (CIBI)
Knopman, D. S., Knapp, M. J., Gracon, S. I., & Davis, C. S. (1994) · Neurology · doi:10.1212/wnl.44.12.2315 · Cited by 213 · see citing works
Oyama, Y., Fuchs, P. A., Katayama, N., & Noda, K. (1994) · Brain Research · doi:10.1016/0006-8993(94)91431-1 · Cited by 209 · see citing works
Multicenter clinicopathological correlation in dementia
Victoroff, J., Mack, W. J., Lyness, S. A., & Chui, H. C. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1476 · Cited by 185 · see citing works
Free Radicals in the Genesis of Alzheimer's Diseasea
Richardson, J. S. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb23031.x · Cited by 171 · see citing works
Tutorial on modeling ordered categorical response data.
Agresti, A. (1989) · Psychological Bulletin · doi:10.1037/0033-2909.105.2.290 · Cited by 147 · see citing works
Hofferberth, B. (1994) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470090308 · Cited by 134 · see citing works
Reliability of NINDS‐AIREN clinical criteria for the diagnosis of vascular dementia
Lopez, O. L., Larumbe, M. R., Becker, J. T., Rezek, D., Rosen, J., Klunk, W., & DeKosky, S. T. (1994) · Neurology · doi:10.1212/wnl.44.7.1240 · Cited by 103 · see citing works
Cross‐national interrater agreement on the clinical diagnostic criteria for dementia
Baldereschi, M., Amato, M. P., Nencini, P., Pracucci, G., Lippi, A., Amaducci, L. A., Gauthier, S. G., Beatty, L., Quiroga, P. M., Klassen, G. A. H., et al. (1994) · Neurology · doi:10.1212/wnl.44.2.239 · Cited by 99 · see citing works
Observations and Suggestions on Antidementia Drug Development
Leber, P. D. (1996) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199601031-00009 · Cited by 87 · see citing works
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.
Kramer‐Ginsberg, E., Mohs, R. C., Aryan, M., Lobel, D., Silverman, J. M., Davidson, M., & Davis, K. L. (1988) · PubMed · Cited by 83 · see citing works
Dahlke, F., Lohaus, A., & Gutzmann, H. (1992) · PubMed · Cited by 83 · see citing works
Development and Validation of the Geriatric Evaluation by Relative's Rating Instrument (Gerri)
Schwartz, G. E. (1983) · Psychological Reports · doi:10.2466/pr0.1983.53.2.479 · Cited by 81 · see citing works
Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction
(1995) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(95)90079-9 · Cited by 61 · see citing works
Nimodipine in the Treatment of Probable Alzheimerʼs Disease
Morich, F., Bieber, F., Lewis, J. M., et al. (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199611040-00001 · Cited by 60 · see citing works
α2-Adrenoceptor Changes During Cerebral Ageing. The Effect ofGinkgo bilobaExtract
Huguet, F., & Tarrade, T. (1992) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1992.tb14357.x · Cited by 58 · see citing works
CENTRAL NERVOUS SYSTEM EFFECTS OF GINKGO BILOBA, A PLANT EXTRACT
Itil, T. M., Eralp, E., Tsambis, E., Itil, K. Z., & Stein, U. (1996) · American Journal of Therapeutics · doi:10.1097/00045391-199601000-00009 · Cited by 56 · see citing works
NCDEU update. Natural product formulations available in europe for psychotropic indications.
Cott, J. M. (1995) · PubMed · Cited by 47 · see citing works
Krištofíková, Z., & Klaschka, J. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106599 · Cited by 36 · see citing works
Clinical Psychopharmacology of Ginkgo Biloba Extract
Warburton, D. M. (1988) · Springer eBooks · doi:10.1007/978-3-642-73686-5_37 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Miller, L. G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.20.2200 · Cited by 809 · see citing works
Sex, stress and the hippocampus: allostasis, allostatic load and the aging process
MCEWEN, B. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00027-1 · Cited by 753 · see citing works
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works
Dominguez, L. J., Veronese, N., Vernuccio, L., Catanese, G., Inzerillo, F., Salemi, G., & Barbagallo, M. (2021) · Nutrients · doi:10.3390/nu13114080 · Cited by 433 · see citing works
Ahmed, T., & Gilani, A.-H. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.09.010 · Cited by 301 · see citing works
Medicinal plants and Alzheimer’s disease: From ethnobotany to phytotherapy
Perry, E. K., Pickering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. L. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991772808 · Cited by 285 · see citing works
Confusional State in Stroke: Relation to Preexisting Dementia, Patient Characteristics, and Outcome
Hénon, H., Lebert, F., Durieu, I., Godefroy, O., Lucas, C., Pasquier, F., & Leys, D. (1999) · Stroke · doi:10.1161/01.str.30.4.773 · Cited by 168 · see citing works
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162 · see citing works
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156 · see citing works
Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer’s disease
Ahmed, T., Enam, S. A., & Gilani, A. H. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.078 · Cited by 156 · see citing works
Effects of Ginkgo biloba on dementia: an overview of systematic reviews
Yuan, Q., Wang, C.-W., Shi, J., & Lin, Z.-X. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.005 · Cited by 148 · see citing works
Divino da Rocha, M., Pereira Dias Viegas, F., Cristina Campos, H., Carolina Nicastro, P., Calve Fossaluzza, P., Alberto Manssour Fraga, C., J. Barreiro, E., & Viegas, C. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794480429 · Cited by 126 · see citing works
Liu, H., Ye, M., & Guo, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01688 · Cited by 116 · see citing works
The immunology of traumatic brain injury: a prime target for Alzheimer’s disease prevention
Giunta, B., Obregon, D., Velisetty, R., Sanberg, P. R., Borlongan, C. V., & Tan, J. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-185 · Cited by 112 · see citing works
Ginkgo biloba in Alzheimer’s disease: A systematic review
Janßen, I. M., Sturtz, S., Skipka, G., Zentner, A., Garrido, M. V., & Busse, R. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0844-8 · Cited by 78 · see citing works
Phytotherapy: A promising approach for the treatment of Alzheimer's disease
John, O. O., Amarachi, I. S., Chinazom, A. P., Adaeze, E., Kale, M. B., Umare, M. D., & Upaganlawar, A. B. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100030 · Cited by 69 · see citing works
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55 · see citing works
Nathan, P. J., Tanner, S., Lloyd, J., Harrison, B., Curran, L., Oliver, C., & Stough, C. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.544 · Cited by 47 · see citing works
No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia
Rainer, M., Kraxberger, E., Haushofer, M., Mucke, H. A. M., & Jellinger, K. A. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070011 · Cited by 46 · see citing works
Su, E., Yang, M., Cao, J., Lu, C., Wang, J., & Cao, F. (2017) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2017.1309661 · Cited by 44 · see citing works
Silberstein, R. B., Pipingas, A., Song, J., Camfield, D. A., Nathan, P. J., & Stough, C. (2011) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2011/164139 · Cited by 36 · see citing works
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29 · see citing works
“[126] Randomized, placebo controlled, double-blind study 309 120 mg once daily for 52 weeks ADAS-Cog Modest improvement in cognitive performance measured by ADAS-Cog and noted by caregivers”
BackgroundMethodNatural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review
Klose, J., Griehl, C., Roßner, S., & Schilling, S. (2022) · Biomolecules · doi:10.3390/biom12050694 · Cited by 23 · see citing works
Phytochemicals in Alzheimer disease, the development of clinical trials
Quinn, J., Kaye, J., Montine, T., & Stackman, R. (2004) · Pharmaceutical Biology · doi:10.3109/138802090893531 · Cited by 8 · see citing works
- Authors
- Le Bars, P. L.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1997-10-22
- Volume
- 278
- Issue
- 16
- Pages
- 1327
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2168910384
- Cited by
- 966
- References
- 37
- Citations by year
- 2026: 8 · 2025: 3 · 2024: 12 · 2023: 8 · 2022: 12 · 2021: 17 · 2020: 16 · 2019: 14 · 2018: 11 · 2017: 13 · 2016: 18 · 2015: 21 · 2014: 25 · 2013: 22 · 2012: 32
- FWCI
- 167.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Ginkgo biloba and Cashew Applications
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Ginkgo biloba extract EGb 761, Alzheimer's disease, multi-infarct dementia, dementia treatment, cognitive function, social functioning, ADAS-Cog, Gerris, drug safety, herbal medicine, adverse events, medication adherence, cost-effectiveness, cost-benefit analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
